DCAL share price, P/E, ROE & financials

On 6 Nov 2026, Dishman Carbogen Amcis was priced at ₹156.64, or 152.1× trailing earnings, against an industry P/E of 49.1×, and the shares are 43% below their 52-week high. It earns ROCE of 2.7% and ROE of 1.6%, and sales grew 7.5% a year over 3 years. Debt is 0.46× equity. It is a small-cap company with a market cap of ₹2,456 Cr, ranked 8th of 20 Biotechnology companies by market cap; the shares fell 47% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹155.20
Day high: ₹157.50
Day low: ₹153.20
Prev. close: ₹157.52
Volume: 87.3K

Health check

1 fair · 5 to check

ReturnsBehind
−47.1% over a year, better than 0 of 7 peers.
Price tagPricier
P/E 152.1 vs industry 49.1.
GrowthSlow
Sales +7.5% a year over 3 years.
ProfitabilityWeak
ROCE 2.7% vs peer median 16.7%.
Balance sheetFair
Debt 0.46× equity, interest covered 1.7×, Piotroski 7 of 9.
Red flags5 to check
Return on equity is low at 1.6%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Biotechnology

19 listed peers. Screen the industry

Small cap

₹2,456 Cr, #8 of 20 in its industry by size.

Defensive

Beta 0.72 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹2,901 Cr · profit ₹16 Cr

Market cap: ₹2,456 Cr; Small cap
P/E: 152.1; Industry 49.1
Price to book: 0.37; Peers 4.68
Dividend yield: 0.00%
ROE: 1.6%; Peers 14.3%
ROCE: 2.7%; Peers 16.7%
Debt to equity: 0.46; Debt ₹3,076 Cr
EPS (TTM): ₹1.03; Face value ₹2
OPM (TTM): 16.1%; Net margin 0.6%
Sales growth: −4.3%; Latest quarter vs a year ago
Profit growth: −347.2%; Latest quarter vs a year ago
Price to sales: 0.85; EV/EBITDA 9.0

Strengths

Positive operating cash flow in each of the last 4 years.

Risks to check

Return on equity is low at 1.6%.
Quarterly profit down 347.2% on a year ago.
Quarterly sales down 4.3% on a year ago.
P/E of 152.1 against an industry P/E of 49.1.
43% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Dishman Carbogen Amcis

Dishman Carbogen Amcis Limited provides contract development and manufacturing organization (CDMO) services for the pharmaceutical and healthcare industries worldwide. It operates through Integrated CDMO Platform and Marketable Molecules segments. The company offers cholesterol and vitamin D analogs; soft gel capsules and formulations; intermediate and active pharmaceutical ingredients (APIs) which cover specific therapeutic areas, such as anesthetics,…

Headquarters: Ahmedabad
Employees: 934
Sector: Healthcare
ISIN: INE385W01011
Website: imdcal.com

Price range

52 weeks

₹128.50₹274.30

Today

₹153.20₹157.50

Avg volume (3M): 2.6 L
1-year return: minus 47.1%
From 52-week high: minus 42.9%

Peers · Biotechnology

Compare with peers Screen the whole industry

Company
BIOCONBiocon	365.10	plus 0.86%	59,794	122.5	1.73	2.8%	1.0%	19.4%	15.3%	−5.9%	0.14%	minus 4.9%
ANTHEMAnthem Biosciences	915.55	plus 0.22%	51,594	84.6	15.74	26.8%	20.4%	41.4%	26.2%	15.4%	0.22%	plus 30.1%
ONESOURCEOnesource Specialty Pharma	1,599.80	plus 1.13%	18,346	–	3.10	0.3%	0.0%	23.5%	232.3%	–	0.00%	minus 13.7%
CONCORDBIOConcord Biotech	632.60	minus 5.96%	13,236	47.4	6.48	16.7%	14.3%	34.5%	8.0%	2.8%	0.60%	minus 7.5%
BLUEJETBlue Jet Healthcare	553.80	minus 3.91%	9,607	34.5	4.52	24.0%	19.9%	31.4%	9.4%	15.7%	0.22%	minus 5.0%
SUPRIYASupriya Lifescience	695.80	minus 19.99%	5,600	28.2	4.68	22.3%	19.1%	21.4%	21.2%	32.5%	0.14%	plus 9.2%
ZOTAZota Health Care	1,231.10	plus 1.01%	4,264	–	6.82	−7.3%	−24.1%	0.1%	56.7%	–	0.08%	minus 21.9%
DCALDishman Carbogen Amcis	156.64	minus 0.56%	2,456	152.1	0.37	2.7%	1.6%	16.1%	7.5%	–	0.00%	minus 47.1%
Median of 7 peers	–	0.22%	13,236	47.4	4.68	16.7%	14.3%	23.5%	21.2%	15.4%	0.14%	−5.0%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Mar 25	Jun 25	Dec 25	Mar 26	Jun 26
716	708	720	851	678
–	–	–	+18.9%	minus 4.3%
564	567	607	688	618
153	141	113	163	60.1
21.3%	19.9%	15.7%	19.1%	8.9%
8	24.8	6.7	16.4	18.2
42.1	42.8	45.8	43.3	37.1
79.1	81.4	84.4	88.8	90.7
−11.8	−2.7	–	−1.2	−1.7
27.7	38.7	−10.4	46.1	−51.2
−55.6%	39.5%	−24.2%	52.9%	−13.0%
43.1	23.4	−13	21.7	−57.9
–	–	–	minus 49.5%	minus 347.2%
2.75	1.49	-0.83	1.39	-3.69

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +7.5%
ROE: 1.6%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
2,315	2,544	2,642	2,878
–	+9.9%	+3.9%	+8.9%
2,015	2,274	2,203	2,341
301	270	439	537
13.0%	10.6%	16.6%	18.6%
51.4	42.1	43.2	64.3
74.4	113	152	154
281	311	294	339
−51.4	−9.6	−18	−3.6
−54.6	−122	19.3	105
45.4%	−25.5%	83.2%	7.1%
−29.8	−153	3.2	97.5
-1.90	-9.79	0.21	6.22

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
31.4	31.4	31.4	31.4
5,778	5,596	5,800	6,646
2,209	2,313	2,389	3,076
1,435	1,641	1,779	2,170
9,454	9,581	9,999	11,923
3,235	3,236	3,200	3,562
1,004	505	281	394
72.1	78.9	72	75.3
358	431	476	983
4,785	5,330	5,970	6,909
9,454	9,581	9,999	11,923

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
266	379	371	491
−494	−230	−192	−245
250	−22.2	−102	201
21.5	128	77	447
−620	−303	−217	−267
−354	76.2	155	225

Shareholding pattern

Source: NSE filings

59.3%

promoters

Promoters59.32%
Public40.68%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	59.32%	40.68%	0.00
30 Jun 2026	59.32%	40.68%	0.00
31 Mar 2026	59.32%	40.68%	0.00
31 Dec 2025	59.32%	40.68%	0.00
30 Sep 2025	59.32%	40.68%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you